Victory Capital Management Inc. Boosts Position in Editas Medicine Inc (EDIT)

Victory Capital Management Inc. increased its stake in Editas Medicine Inc (NASDAQ:EDIT) by 37.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 62,002 shares of the company’s stock after purchasing an additional 16,800 shares during the quarter. Victory Capital Management Inc.’s holdings in Editas Medicine were worth $1,411,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new position in Editas Medicine in the 3rd quarter valued at approximately $9,549,000. Vanguard Group Inc grew its stake in Editas Medicine by 3.9% in the 3rd quarter. Vanguard Group Inc now owns 3,729,579 shares of the company’s stock valued at $118,675,000 after buying an additional 141,609 shares in the last quarter. Valiant Capital Management L.P. purchased a new position in Editas Medicine in the 3rd quarter valued at approximately $12,085,000. Oppenheimer & Co. Inc. purchased a new position in Editas Medicine in the 3rd quarter valued at approximately $595,000. Finally, Vanguard Group Inc. grew its stake in Editas Medicine by 3.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,729,579 shares of the company’s stock valued at $118,675,000 after buying an additional 141,609 shares in the last quarter. Institutional investors and hedge funds own 69.92% of the company’s stock.

A number of research firms recently weighed in on EDIT. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. ValuEngine upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 4th. BTIG Research began coverage on shares of Editas Medicine in a research note on Thursday, February 7th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Editas Medicine in a research note on Tuesday, January 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $42.50.

EDIT opened at $23.64 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.14 and a quick ratio of 13.13. Editas Medicine Inc has a one year low of $17.80 and a one year high of $45.02.

In other news, CFO Andrew A. F. Hack sold 6,895 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $21.39, for a total transaction of $147,484.05. Following the completion of the transaction, the chief financial officer now directly owns 6,895 shares in the company, valued at approximately $147,484.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vickesh Myer sold 3,000 shares of the business’s stock in a transaction on Wednesday, February 20th. The shares were sold at an average price of $20.42, for a total transaction of $61,260.00. Following the transaction, the insider now owns 3,000 shares of the company’s stock, valued at $61,260. The disclosure for this sale can be found here. Insiders have sold a total of 54,895 shares of company stock valued at $1,430,174 over the last 90 days. Company insiders own 5.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2019/03/03/victory-capital-management-inc-boosts-position-in-editas-medicine-inc-edit.html.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Featured Article: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit